Tuesday, January 17, 2012

Pfizer, Medivation end development of potential Alzheimer's treatment

Please Help Support Alzheimer's Research Today! 
Your Alzheimer's donation will help billions live without it.

( dimebon failed in another late-stage clinical trial )
Drug developers Pfizer and Medivation are ending the development of a potential Alzheimer's disease treatment after the drug yielded disappointing results in a late-stage clinical study.

The companies say dimebon failed to achieve statistically significant improvements in cognitive ability and measurements of self care and daily function in patients with mild-to-moderate cases of the disease. The study involved about 1,000 patients who had dimebon added to their ongoing treatment with Alzheimer's drug donepezil.

The companies are ending development of dimebon, as well as their agreement to co-develop and market the potential treatment. Continue to read: fox6now.com


The benefits of coffee

Researchers have known for some time that regular coffee drinkers have a lower risk of developing Type 2 diabetes: people who drink four or more cups of coffee each day have a 50 percent lower risk of the disease, with each additional cup associated with a further 7 percent drop in risk. But the cause of this bizarre connection has been a source of speculation. Read more: the-scientist.com 

Погода в Беларуси


Posted YVN (AMYLOID @ PHOTO). 
at

No comments:

Post a Comment